Sonoma Pharmaceuticals (SNOA) Income from Non-Controlling Interests (2020 - 2021)
Sonoma Pharmaceuticals' (SNOA) quarterly Income from Non-Controlling Interests came in at $1.0 million in Q4 2021, up 372.7% year-on-year from $213453.4 in Q4 2020, and up 202.1% quarter-over-quarter from $334000.0 in Q3 2021.
Sonoma Pharmaceuticals (SNOA) Income from Non-Controlling Interests (2020 - 2021) Analysis & Trends
Sonoma Pharmaceuticals' Income from Non-Controlling Interests history runs 2 years deep, the most recent figure standing at $1.0 million for Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.06 Bn | 87.19 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | - |
| 3 | Zoetis | 32.39 Bn | 30.45 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 27.59 Bn | 23.53 Bn | 4.39 Bn | 395,346.10 |
| 5 | United Therapeutics | 23.19 Bn | 21.04 Bn | 648.10 Mn | - |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - | - |
| 7 | Viatris | 20.27 Bn | 18.46 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 18.00 Bn | 16.69 Bn | 800.70 Mn | -12.70 Mn |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | - |
| 10 | Sonoma Pharmaceuticals | 1.95 Mn | -445,560.06 | 2.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 1.01 Mn |
| Sep 30, 2021 | 334,000.00 |
| Jun 30, 2021 | 791,000.00 |
| Dec 31, 2020 | -370,000.00 |
| Sep 30, 2020 | -308,000.00 |
| Jun 30, 2020 | -407,000.00 |